Literature DB >> 29463370

Exchangeability of FITC-SiO₂ Nanoparticles Between Cancer Cells Increases the Range of Drug Delivery.

Guoying Deng, Zizheng Wu, Feng Zhou, Chenyun Dai, Jingpeng Zhao, Yingjie Kang, Qian Wang, Xijian Liu, Yin Wang, Qiugen Wang.   

Abstract

Drug delivery system studies aim to improve nanoparticle (NP) formulation to enable efficient delivery of NPs to tumors. However, NPs must be transported by blood or through direct injection. How NPs leave the circulatory system and how NPs diffuse into a tumor remain unclear, and this uncertainty is a limitation of drug delivery systems. The intimate connection between these questions and metabolism may be related to their biosafety in vivo. Thus, in this study, classical carrier SiO2 NPs were used as typical transport NPs, and fluorescein isothiocyanate (FITC) was used as the representative drug and tracer. As exosome and tunneling nanotubes (TNTs) are the most relevant mechanism for NP transportation and considering the local situation in a tumor, we focused on identifying this phenomenon and investigating TNTs. In conclusion, we effectively demonstrated that NPs can be transferred from cell to cell. Nanotubes may play an important role in this process.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29463370     DOI: 10.1166/jbn.2018.2509

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  2 in total

1.  Differential Exchange of Multifunctional Liposomes Between Glioblastoma Cells and Healthy Astrocytes via Tunneling Nanotubes.

Authors:  Beatrice Formicola; Alessia D'Aloia; Roberta Dal Magro; Simone Stucchi; Roberta Rigolio; Michela Ceriani; Francesca Re
Journal:  Front Bioeng Biotechnol       Date:  2019-12-12

Review 2.  Opportunities and Challenges in Tunneling Nanotubes Research: How Far from Clinical Application?

Authors:  Xiaoning Han; Xiang Wang
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.